menu
    • menu

    Find Insulin manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 61
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    CLINICAL TRIALS

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    19

    API Suppliers

    12

    USDMF

    0

    CEP/COS

    0

    JDMF

    0

    EU WC

    0

    KDMF

    6

    NDC API

    1

    VMF

    3

    Listed Suppliers

    1INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    2

    Others

    FINISHED DOSAGE FORMULATIONS

    96

    FDF Dossiers

    5

    FDA Orange Book

    64

    Europe

    20

    Canada

    0

    Australia

    3

    South Africa

    4

    Listed Dossiers

    61PROSPECTS

    122DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    25RELATED EXCIPIENT COMPANIES

    45EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    420,876,893

    Annual Reports

    25,283

    Regulatory FDF Prices

    NA

    MARKET PLACE

    15

    API

    6

    FDF

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    562

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 9004-10-8, Iletin, Endopancrine, Decurvon, Dermulin, Humilin
    Molecular Formula
    C256H381N65O77S6
    Molecular Weight
    5794  g/mol
    InChI Key
    YAJCHEVQCOHZDC-QMMNLEPNSA-N
    Insulin
    A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
    1 2D Structure

    Insulin

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-oxopropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2R)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1S)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2S)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
    2.1.2 InChI
    InChI=1S/C256H381N65O77S6/c1-29-130(23)202(311-190(337)103-258)250(391)315-200(128(19)20)246(387)286-158(75-82-197(347)348)216(357)281-154(70-77-186(261)333)220(361)306-181-115-402-403-116-182-241(382)303-176(110-323)238(379)293-161(88-122(7)8)224(365)294-167(95-139-53-61-145(328)62-54-139)227(368)282-153(69-76-185(260)332)217(358)289-160(87-121(5)6)222(363)283-157(74-81-196(345)346)219(360)301-173(101-188(263)335)233(374)297-169(97-141-57-65-147(330)66-58-141)230(371)307-180(240(381)302-174(254(395)396)102-189(264)336)114-401-400-113-179(213(354)272-106-191(338)277-152(72-79-194(341)342)215(356)280-150(51-42-84-270-256(266)267)211(352)271-107-192(339)278-165(93-137-46-36-32-37-47-137)226(367)296-166(94-138-48-38-33-39-49-138)229(370)298-170(98-142-59-67-148(331)68-60-142)236(377)318-205(134(27)326)253(394)321-85-43-52-184(321)244(385)284-151(50-40-41-83-257)221(362)319-206(135(28)327)255(397)398)309-247(388)199(127(17)18)314-234(375)163(90-124(11)12)291-228(369)168(96-140-55-63-146(329)64-56-140)295-223(364)159(86-120(3)4)288-209(350)132(25)276-214(355)156(73-80-195(343)344)285-245(386)198(126(15)16)313-235(376)164(91-125(13)14)292-232(373)172(100-144-105-269-119-275-144)300-237(378)175(109-322)279-193(340)108-273-212(353)178(112-399-404-117-183(308-242(181)383)243(384)317-204(133(26)325)251(392)304-177(111-324)239(380)316-203(131(24)30-2)249(390)310-182)305-225(366)162(89-123(9)10)290-231(372)171(99-143-104-268-118-274-143)299-218(359)155(71-78-187(262)334)287-252(393)207(208(265)349)320-248(389)201(129(21)22)312-210(351)149(259)92-136-44-34-31-35-45-136/h31-39,44-49,53-68,104-105,118-135,149-184,198-207,322-331H,29-30,40-43,50-52,69-103,106-117,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,349)(H,268,274)(H,269,275)(H,271,352)(H,272,354)(H,273,353)(H,276,355)(H,277,338)(H,278,339)(H,279,340)(H,280,356)(H,281,357)(H,282,368)(H,283,363)(H,284,385)(H,285,386)(H,286,387)(H,287,393)(H,288,350)(H,289,358)(H,290,372)(H,291,369)(H,292,373)(H,293,379)(H,294,365)(H,295,364)(H,296,367)(H,297,374)(H,298,370)(H,299,359)(H,300,378)(H,301,360)(H,302,381)(H,303,382)(H,304,392)(H,305,366)(H,306,361)(H,307,371)(H,308,383)(H,309,388)(H,310,390)(H,311,337)(H,312,351)(H,313,376)(H,314,375)(H,315,391)(H,316,380)(H,317,384)(H,318,377)(H,319,362)(H,320,389)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,395,396)(H,397,398)(H4,266,267,270)/t130-,131-,132+,133+,134+,135+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182-,183+,184+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+/m1/s1
    2.1.3 InChI Key
    YAJCHEVQCOHZDC-QMMNLEPNSA-N
    2.1.4 Canonical SMILES
    CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(C(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN
    2.1.5 Isomeric SMILES
    CC[C@@H](C)[C@H]1C(=O)N[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](C)CC)NC(=O)CN
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Chain, Insulin B

    2. Iletin

    3. Insulin

    4. Insulin A Chain

    5. Insulin B Chain

    6. Insulin, Regular

    7. Insulin, Sodium

    8. Insulin, Soluble

    9. Novolin

    10. Regular Insulin

    11. Sodium Insulin

    12. Soluble Insulin

    2.2.2 Depositor-Supplied Synonyms

    1. 9004-10-8

    2. Iletin

    3. Endopancrine

    4. Decurvon

    5. Dermulin

    6. Humilin

    7. Insular

    8. Insulyl

    9. Iszilin

    10. Musulin

    11. Insulin-human

    12. Dal-insulinum

    13. Intesulin B

    14. Aerx

    15. Insulin, Dalanated

    16. Insulina Dalanatada

    17. Insulinum Dalanatum

    18. Imusay-131

    19. Insulin Injection

    20. Dalanated Insulin [inn]

    21. Insulina Iniettabile Neutra

    22. Insulini Injectio Neutralis

    23. Injectable Insulini Neutrale

    24. Inyectable Neutro De Insulina

    25. Ccris 5464

    26. Hsdb 3102

    27. Insulin, Dalanated [usan:inn]

    28. Insulinum Dalanatum [inn-latin]

    29. Aerx [insulin Management System]

    30. Insulina Dalanatada [inn-spanish]

    31. Solute Neutre Injectable D'insuline

    32. Hmr 4006

    33. Insulina Iniettabile Neutra [dcit]

    34. Einecs 232-672-8

    35. S.n. 44

    36. Insulini Injectio Neutralis [inn-latin]

    37. Inyectable Neutro De Insulina [inn-spanish]

    38. Solute Neutre Injectable D'insuline [inn-french]

    2.3 Create Date
    2012-12-12
    3 Chemical and Physical Properties
    Molecular Weight 5794 g/mol
    Molecular Formula C256H381N65O77S6
    XLogP3-12.8
    Hydrogen Bond Donor Count78
    Hydrogen Bond Acceptor Count89
    Rotatable Bond Count178
    Exact Mass5791.6287098 g/mol
    Monoisotopic Mass5789.6220002 g/mol
    Topological Polar Surface Area2450 Ų
    Heavy Atom Count404
    Formal Charge0
    Complexity14600
    Isotope Atom Count0
    Defined Atom Stereocenter Count52
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameAfrezza
    PubMed HealthInsulin Human Inhaled (Inhalation route)
    Drug ClassesAntidiabetic, Insulin, Rapid Acting
    Active IngredientInsulin recombinant human
    Dosage FormPowder
    RouteInhalation
    Strength4 units/inh; 8 units/inh
    Market StatusPrescription
    CompanyMannkind

    2 of 2  
    Drug NameAfrezza
    PubMed HealthInsulin Human Inhaled (Inhalation route)
    Drug ClassesAntidiabetic, Insulin, Rapid Acting
    Active IngredientInsulin recombinant human
    Dosage FormPowder
    RouteInhalation
    Strength4 units/inh; 8 units/inh
    Market StatusPrescription
    CompanyMannkind

    4.2 Therapeutic Uses

    INSULIN INJECTION...INSULIN OF CHOICE IN PRESENCE OF UNSTABLE DIABETES WHEN COMPLICATIONS SUCH AS INFECTION, SHOCK, OR SURGICAL TRAUMA OCCUR. ...IS ONLY INSULIN PREPN THAT MAY BE GIVEN IV AS WELL AS SC.

    American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 589

    /INSULIN/ HAS BEEN USED TO PRODUCE CONVULSIVE SHOCK SEIZURES FOR TREATMENT OF CERTAIN PSYCHIATRIC CASES. IT IS ALSO USED FOR TREATMENT OF UNDERWEIGHT INDIVIDUALS, PURPOSE BEING TO STIMULATE APPETITE BY LOWERING LEVEL OF BLOOD SUGAR.

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 901

    RECOMMENDED TECHNIQUE IS TO INJECT INSULIN INTO POCKET BETWEEN FATTY LAYER OF SKIN & UNDERLYING MUSCLE. RECOMMENDED AREAS ARE THIGHS, ABDOMEN, UPPER BACK, & UPPER ARMS. NO ONE SITE IS USED MORE OFTEN THAN EVERY 4-6 WK. PREVENTS TISSUE HYPERTROPHY.

    BURKE EL; AMER J NURS 72 (DEC) 2194-6 (1972)

    STERILE, ACIDIFIED OR NEUTRAL SOLN OF ACTIVE PRINCIPAL OF PANCREAS WHICH AFFECTS GLUCOSE METABOLISM. CONTAINS 40, 80, 100, OR 500 USP INSULIN UNITS/ML. ... ONSET OF ACTION OCCURS WITHIN 1 HR AFTER SUBCUTANEOUS INJECTION, REACHING ITS MAXIMUM IN 2-3 HR. DURATION OF EFFECT, 6-8 HR.

    The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 659

    4.3 Drug Warning

    EVERY DIABETIC PATIENT TAKING INSULIN SHOULD CARRY AN IDENTIFICATION CARD CONTAINING PERTINENT MEDICAL INFORMATION.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1519

    PATIENTS WHO EXPERIENCE ATROPHY OF SC FAT AT SITE OF INJECTION (INSULIN LIPOATROPHY) SHOULD INJECT INSULIN IN AREAS THAT ARE USUALLY COVERED BY CLOTHING; PROBLEM MAY BE MINIMIZED BY CHANGING SITE OF INJECTION FREQUENTLY.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1519

    ...SINCE SEVERAL WEEKS MAY BE REQUIRED TO STABILIZE OSMOTIC EQUILIBRIUM IN THE EYE, ALTERATIONS OF PRESCRIPTIONS FOR CORRECTIVE LENSES SHOULD BE POSTPONED FOR 3-6 WEEKS.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1519

    ...DIABETIC PT RECEIVING THYROID HORMONE REPLACEMENT THERAPY SHOULD BE MONITORED FOR INCR INSULIN REQUIREMENTS. /MECHANISM OF ACTION ONLY THEORIZED/

    Evaluations of Drug Interactions. 2nd ed. and supplements. Washington, DC: American Pharmaceutical Assn., 1976, 1978., p. 553

    OVERDOSAGE CAN BE FATAL.

    Hawley, G.G. The Condensed Chemical Dictionary. 9th ed. New York: Van Nostrand Reinhold Co., 1977., p. 468

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Hypoglycemic Agents

    Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)

    5.2 Absorption, Distribution and Excretion

    FRACTION OF...EXOGENOUS INSULIN IN PLASMA MAY BE ASSOC WITH CERTAIN PROTEINS, CHIEFLY ALPHA- & BETA-GLOBULINS. ...THESE ASSOC ARE OF IMPORTANCE FOR TRANSPORT OF INSULIN...WHICH APPEARS TO CIRCULATE IN BLOOD & LYMPH... VOL OF DISTRIBUTION OF INSULIN APPROXIMATES VOL OF EXTRACELLULAR FLUID.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1511

    WHILE INSULIN CAN BE DETECTED IN URINE, THE KIDNEY FILTERS & REABSORBS THE HORMONE & RENAL EXCRETION IS NOT MAJOR ROUTE OF ELIMINATION. LIVER & KIDNEY ARE OF PRIMARY IMPORTANCE IN DEGRADING HORMONE & EACH IS CAPABLE OF DESTROYING ALMOST 40% OF INSULIN PRODUCED PER DAY (30 TO 50 UNITS).

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1511

    SEVERE IMPAIRMENT OF RENAL FUNCTION APPEARS TO AFFECT RATE OF DISAPPEARANCE OF CIRCULATING INSULIN TO GREATER EXTENT THAN DOES HEPATIC DISEASE...

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1511

    IN ABSENCE OF INSULIN THERE IS MARKED REDUCTION IN RATE OF TRANSPORT OF GLUCOSE ACROSS CERTAIN CELL MEMBRANES.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1512

    SERIAL IMMUNOREACTIVE INSULIN CONCN WERE MUCH HIGHER AFTER EXERCISE THAN THOSE ASSOC WITH REST. THE ENHANCED ABSORPTION OF INSULIN FROM SC TISSUE IS PROBABLY THROUGH AN INCR IN BLOOD FLOW IN INJECTED LIMB.

    DANDONA P ET AL; BR MED J 1 (FEB) 479-80 (1978)

    5.3 Metabolism/Metabolites

    IN-VITRO EXPT SUGGESTS 2 SYSTEMS INVOLVED IN DEGRADATION OF INSULIN BY LIVER: (1) ENZYME TERMED GLUTATHIONE-INSULIN TRANSHYDROGENASE, WHICH UTILIZES REDUCED GLUTATHIONE TO REDUCE DISULFIDE BRIDGES; & (2) PROTEOLYTIC ENZYME(S) THAT CLEAVES REDUCED & SEPARATED CHAINS TO PEPTIDES & AMINO ACIDS.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1511

    A PROTEOLYTIC ENZYME THAT DEGRADES BOTH INSULIN & GLUCAGON HAS BEEN EXTENSIVELY PURIFIED FROM RAT SKELETAL MUSCLE.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1512

    5.4 Biological Half-Life

    PLASMA HALF-LIFE OF INSULIN INJECTED INTRAVENOUSLY IS LESS THAN 9 MINUTES IN MAN.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1511

    5.5 Mechanism of Action

    INSULIN HAS DIRECT INHIBITORY EFFECT ON LIPASE CONCERNED WITH MOBILIZATION OF FATTY ACIDS, WHILE GROWTH HORMONE, GLUCOCORTICOIDS, THYROID HORMONES & CATECHOLAMINES ENHANCE LIPOLYSIS.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1515

    IN ABSENCE OF INSULIN THERE IS ABNORMALLY HIGH RATE OF CONVERSION OF PROTEIN TO GLUCOSE. ... PROTEINS & AMINO ACIDS ARE CONVERTED TO GLUCOSE @ ABNORMALLY HIGH RATE IN INSULIN DEFICIENCY. THE LIVER IS SITE OF CONVERSION. PROTEIN & AMINO ACIDS ARE MOBILIZED FROM PERIPHERAL TISSUES.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1514

    INSULIN ACTS TO.../STIMULATE/ GLYCOGEN SYNTHESIS.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1515

    MECHANISM OF IMPORTANT ACTIONS OF INSULIN TO ENHANCE FACILITATED DIFFUSION OF GLUCOSE & ACTIVE TRANSPORT OF AMINO ACIDS ARE NOT KNOWN.

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1516

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

    Details:

    Frexalimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.


    Lead Product(s): Frexalimab,Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 01, 2023

    Sanofi Company Banner

    01

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Frexalimab,Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adole...

    Details : Frexalimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 01, 2023

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes

    Details:

    Insulin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 1.


    Lead Product(s): Insulin,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Hormone

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 17, 2017

    Sanofi Company Banner

    02

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Insulin,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes

    Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Undisclosed

    Product Type : Hormone

    Upfront Cash : Inapplicable

    October 17, 2017

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia...

    Details:

    Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dyslipidemias.


    Lead Product(s): Alirocumab,Insulin

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 30, 2015

    Sanofi Company Banner

    03

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Alirocumab,Insulin

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy i...

    Details : Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dyslipidemias.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    December 30, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus P...

    Details:

    SAR438544 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.


    Lead Product(s): SAR438544,Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 18, 2015

    Sanofi Company Banner

    04

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : SAR438544,Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 i...

    Details : SAR438544 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    December 18, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Typ...

    Details:

    Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.


    Lead Product(s): Alirocumab,Lipid-Modifying Therapy,Insulin

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 23, 2015

    Sanofi Company Banner

    05

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Alirocumab,Lipid-Modifying Therapy,Insulin

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Ther...

    Details : Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    October 23, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    TOFO Insulin Combination Trial

    Details:

    Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Tofogliflozin,Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Miscellaneous

    Sponsor: Kowa Company

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 25, 2014

    Sanofi Company Banner

    06

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Tofogliflozin,Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Kowa Company

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    TOFO Insulin Combination Trial

    Details : Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 25, 2014

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    ManKind Presents Positive Original Analyses of Afrezza® Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions

    Details:

    Company announced that new data from clinical studies of Afrezza® demostrating safe and effective dosing, its association with weight loss in patients with type 2 diabetes, and an evaluation of a comprehensive two year safety study showing that significant changes in FEV1.


    Lead Product(s): Technosphere Insulin,Insulin,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Afrezza

    Study Phase: Approved FDFProduct Type: Hormone

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 15, 2020

    Company Banner

    07

    Mankind Pharma

    India
    arrow
    CPhI China
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Lead Product(s) : Technosphere Insulin,Insulin,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ManKind Presents Positive Original Analyses of Afrezza® Clinical Data at American Diabetes Associ...

    Details : Company announced that new data from clinical studies of Afrezza® demostrating safe and effective dosing, its association with weight loss in patients with type 2 diabetes, and an evaluation of a comprehensive two year safety study showing that signific...

    Product Name : Afrezza

    Product Type : Hormone

    Upfront Cash : Inapplicable

    June 15, 2020

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    MannKind Announces FDA Approval of Afrezza® for Children with Diabetes aged 6+

    Details:

    Insulin Human, a hormone targeting the insulin receptor, shows promise in treating type 1 diabetes.


    Lead Product(s): Insulin,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Afrezza

    Study Phase: Approved FDFProduct Type: Hormone

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 29, 2026

    blank

    08

    Mannkind

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Mannkind

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MannKind Announces FDA Approval of Afrezza® for Children with Diabetes aged 6+

    Details : Insulin Human, a hormone targeting the insulin receptor, shows promise in treating type 1 diabetes.

    Product Name : Afrezza

    Product Type : Hormone

    Upfront Cash : Inapplicable

    May 29, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Comparative Clinical Trial of Pharmacokinetics and Pharmacodynamics of Human Insulin Injection

    Details:

    USLIN R (Insulin) is a hormone drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.


    Lead Product(s): Insulin,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: USLIN R

    Study Phase: Phase IProduct Type: Hormone

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 27, 2026

    blank

    09

    Zhuhai United Laboratories Co ., Ltd.

    China
    arrow
    PEGS Boston Summit
    Not Confirmed

    Zhuhai United Laboratories Co ., Ltd.

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Comparative Clinical Trial of Pharmacokinetics and Pharmacodynamics of Human Insulin Injection

    Details : USLIN R (Insulin) is a hormone drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.

    Product Name : USLIN R

    Product Type : Hormone

    Upfront Cash : Inapplicable

    May 27, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Clinical Trials of IBI3035 in Healthy Subjects

    Details:

    IBI3035 is a large molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.


    Lead Product(s): Insulin,Insulin Icodec

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Hormone

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 15, 2026

    blank

    10

    Innovent Biologics

    China
    arrow
    PEGS Boston Summit
    Not Confirmed

    Innovent Biologics

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin,Insulin Icodec

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Clinical Trials of IBI3035 in Healthy Subjects

    Details : IBI3035 is a large molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.

    Product Name : Undisclosed

    Product Type : Hormone

    Upfront Cash : Inapplicable

    May 15, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Parenteral

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    india-flag.png
    Injectable Grade Insulin API needed in India [ENA24801]
    A company that focuses on the manufacturing of high-quality liquid sterile formulations in small volume glass ampoules and dry powder vials is looking for suppliers of Injectable Grade Insulin API for development purposes. The suppliers must support this enquiry with DMF, GMP & CoA.
    13 Dec 2025

    Reply

    13 Dec 2025

    Reply text-arrow

    Reply Comment (2)

    13 Dec 2025

    Mexico.png
    Insulin (100 g) API needed in Mexico [ENA22991]
    A globally-renowned pharmaceutical company that focuses on research, development, manufacturing and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas is looking for suppliers of Insulin (100 g) API for development purposes. The suppliers must support this enquiry with GMP & CoA.
    17 May 2025

    Reply

    17 May 2025

    Reply text-arrow

    Reply Comment (3)

    17 May 2025

    india-flag.png
    EP & Human Grade Insulin (20 kg) API needed in India [ENA22351]
    A leading pharmaceutical company with over three decades of experience in manufacturing of active ingredients & intermediates is looking for suppliers of EP & Human Grade Insulin (20 kg) API for commercial purposes. The suppliers must support this enquiry with GMP & CoA.
    14 Mar 2025

    Reply

    14 Mar 2025

    Reply text-arrow

    Reply Comment (3)

    14 Mar 2025

    unitedkingdom_new.png
    Insulin (0.1 kg) API needed in United Kingdom [ENA18837]
    A CDMO that focuses on providing services from API to clinical batch supply, formulation development services & analytical and bioanalytical methods is looking for suppliers of Insulin (0.1 kg) API for development purposes. The suppliers must support this enquiry with GMP, CEP & CoA.
    29 Dec 2023

    Reply

    29 Dec 2023

    Reply text-arrow

    Reply Comment (4)

    29 Dec 2023

    india-flag.png
    Insulin API needed in India [ENA17637]
    A company that deals in the trading of various pharmaceutical products is looking for suppliers of Insulin API for commercial purposes. The suppliers must support this enquiry with CoA.
    22 Jul 2023

    Reply

    22 Jul 2023

    Reply text-arrow

    Reply Comment (2)

    22 Jul 2023

    United_States_of_America.png
    Insulin API needed in the United States [ENA14899]
    A company that deals in various pharmaceutical products is looking for suppliers of Insulin API for commercial purpose. The suppliers must support this enquiry with CoA.
    02 Sep 2022

    Reply

    02 Sep 2022

    Reply text-arrow

    Reply Comment (13)

    02 Sep 2022

    CzechRepublic.png
    Insulin API needed in Czech Republic [ENA14449]
    A company that deals in distribution of various pharmaceutical products is looking for suppliers of Insulin API for commercial purpose. The required quantity is 500 g, 1 kg & 10 kg. The suppliers must support this enquiry with CoA.
    25 Jul 2022

    Reply

    25 Jul 2022

    Reply text-arrow

    Reply Comment (5)

    25 Jul 2022

    Egypt.png
    Insulin API needed in Egypt [ENA11392]
    Suecal, a company that deals in researching, developing, and manufacturing a wide range of pharmaceutical products is looking for suppliers of Insulin API for both development & commercial purpose. The suppliers must support this enquiry with FDA & EMEA. The company is also open for tech transfer along with the API. Interested suppliers can contact them via their email: mohamed.gaafar@suecal.com.
    14 Sep 2021

    Reply

    14 Sep 2021

    Reply text-arrow

    Reply Comment (5)

    14 Sep 2021

    india-flag.png
    Insulin Human, Insulin Aspart and other APIs needed in India [ENA05086]
    A multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients is looking for suppliers of Insulin APIs mentioned below for research and development purposes. 1. Insulin Human 2. Insulin Aspart 3. Insulin Animal.
    06 Sep 2019

    Reply

    06 Sep 2019

    Reply text-arrow

    Reply Comment (3)

    06 Sep 2019

    Georgia.png
    Insulin (Novogel pens), Yellow Fever and other vaccines needed in Georgia [ENA02248]
    International Medical Support Services (IMSS) Ltd Georgia is a leader in quality healthcare provision and emergency readiness response is looking for suppliers of the following pharmaceutical products: 1) Insulin 2) Yellow Fever Vaccine 3) Typhoid Vaccine 4) TwinRix Vaccine 5) Rabies Vaccine 6) Hepatitis A& B (Adult and Paediatric) Vaccine 7) Meningococcal (Groups A, C, Y and W-135) 8) Diphtheria Vaccine 9) Tetanus Vaccine Interested suppliers must contact Jane via E-mail: administrator@imss.ge or Tel: 0322920928.
    10 Oct 2018

    Reply

    10 Oct 2018

    Reply text-arrow

    Reply Comment (0)

    10 Oct 2018

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CLINICAL TRIALS

    read-more
    read-more

    01

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT01889667

    Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple O...

    Product Description : ORMD-0801 (Oral Insulin) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : C

    Date Of Registration : 19-06-2013

    Condition : Type 2 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT02094534

    A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : C

    Date Of Registration : 20-03-2014

    Condition : Type 1 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT02496000

    Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Multiple...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : C

    Date Of Registration : 08-07-2015

    Condition : Type 2 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT02954601

    A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : C

    Date Of Registration : 13-10-2016

    Condition : Type 2 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT02535715

    A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Oramed Ltd.

    Recruitment Status : C

    Date Of Registration : 12-08-2015

    Condition : Type 1 diabetes mellitus

    Product Type : Large molecule

    Sponsor : The University of Texas Health Science Center at San Antonio

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Hepatology (Liver, Pancreatic,...

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Hepatology (Liver, Pancreatic,...

    Interventions : Insulin

    Location : Israel

    Receptors : Insulin receptor agonist

    Trial ID : NCT02653300

    An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Soft gel capsule

    Collaborator : Hadassah Medical Organ...

    Recruitment Status : R

    Date Of Registration : 24-12-2015

    Condition : Nonalcoholic steatohepatitis

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT04150107

    A Phase 2 Randomized, Open Label Crossover Study to Compare ORMD-0801 Given Once Daily at Bedtim...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : R

    Date Of Registration : 31-10-2019

    Condition : Type 1 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : United States

    Receptors : Insulin receptor agonist

    Trial ID : NCT03467932

    A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safe...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : C

    Date Of Registration : 01-03-2018

    Condition : Type 2 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Ltd.

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : India

    Receptors : Insulin receptor agonist

    Trial ID : CTRI/2009/091/000371

    A Phase 2b, comparative, two arm randomized, placebo-controlled, double blinded multi-centric st...

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Integrium

    Recruitment Status : R

    Date Of Registration : 10-07-2009

    Condition : Type 2 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Inc

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Phase II

    Therapeutic Area: Endocrinology

    Interventions: Insulin

    Highest Development Status: : Phase II

    Therapeutic Area : Endocrinology

    Interventions : Insulin

    Location : Israel

    Receptors : Insulin receptor agonist

    Trial ID : NCT00867594

    Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients

    Product Description : ORMD-0801 (Oral Insulin) capsule has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment.

    Product Status : Approved

    Dosage Form : Capsule

    Collaborator : Oramed Ltd.

    Recruitment Status : C

    Date Of Registration : 22-03-2009

    Condition : Type 1 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Hadassah Medical Organization

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    11

    Oramed Pharmaceuticals

    PEGS Boston Summit
    Not Confirmed
    arrow

    Oramed Pharmaceuticals

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Highest Development Status: Undisclosed

    Therapeutic Area: Endocrinology

    Interventions: Exenatide,Insulin

    Highest Development Status: : Undisclosed

    Therapeutic Area : Endocrinology

    Interventions : Exenatide,Insulin

    Location :

    Receptors : Insulin receptor agonist||Glucagon-like peptide 1 receptor agonist

    Trial ID :

    Oral Combination Therapy for the Management of T2DM, by Combining the Advantages of ORMD-0801 an...

    Product Description : ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.

    Product Status : Approved

    Dosage Form : Oral

    Collaborator : NA

    Recruitment Status :

    Date Of Registration : NA

    Condition : Type 2 diabetes mellitus

    Product Type : Large molecule

    Sponsor : Oramed Inc

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Others

    read-more
    read-more

    01

    XYZ Pharma

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    XYZ Pharma

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Insulin Human (100 mg)

    CAS Number : 11061-68-0

    Quantity Per Vial : 100

    Sale Unit : mg

    Price : $285.00

    Details : Material Origin- Recombinant; USMCA- Yes; KOR...

    Monograph :

    Storage : Cold Shipment Required

    Code/Batch No : Catalog #1342106 / R12790

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    XYZ Pharma

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    XYZ Pharma

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Insulin Pork (50 mg)

    CAS Number : 12584-58-6

    Quantity Per Vial : 12.5

    Sale Unit : mg

    Price : $280.00

    Details : Material Origin- Animal-Pig; USMCA- No; KORUS...

    Monograph :

    Storage : Cold Shipment Required

    Code/Batch No : Catalog #1342300 / R052Q0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ANALYTICAL

    Upload your methods for free, ask us

    Analytical Methods

    read-more
    read-more

    ABOUT THIS PAGE

    Looking for 9004-10-8 / Insulin API manufacturers, exporters & distributors?

    Insulin manufacturers, exporters & distributors 1

    86

    PharmaCompass offers a list of Insulin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Insulin manufacturer or Insulin supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Insulin manufacturer or Insulin supplier.

    API | Excipient name

    Insulin

    Synonyms

    9004-10-8, Iletin, Endopancrine, Decurvon, Dermulin, Humilin

    Cas Number

    9004-10-8

    About Insulin

    A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

    Human Protaphane Manufacturers

    A Human Protaphane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Human Protaphane, including repackagers and relabelers. The FDA regulates Human Protaphane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Human Protaphane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Human Protaphane manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Human Protaphane Suppliers

    A Human Protaphane supplier is an individual or a company that provides Human Protaphane active pharmaceutical ingredient (API) or Human Protaphane finished formulations upon request. The Human Protaphane suppliers may include Human Protaphane API manufacturers, exporters, distributors and traders.

    click here to find a list of Human Protaphane suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Human Protaphane USDMF

    A Human Protaphane DMF (Drug Master File) is a document detailing the whole manufacturing process of Human Protaphane active pharmaceutical ingredient (API) in detail. Different forms of Human Protaphane DMFs exist exist since differing nations have different regulations, such as Human Protaphane USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Human Protaphane DMF submitted to regulatory agencies in the US is known as a USDMF. Human Protaphane USDMF includes data on Human Protaphane's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Human Protaphane USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Human Protaphane suppliers with USDMF on PharmaCompass.

    Human Protaphane NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Human Protaphane as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Human Protaphane API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Human Protaphane as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Human Protaphane and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Human Protaphane NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Human Protaphane suppliers with NDC on PharmaCompass.

    Human Protaphane GMP

    Human Protaphane Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Human Protaphane GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Human Protaphane GMP manufacturer or Human Protaphane GMP API supplier for your needs.

    Human Protaphane CoA

    A Human Protaphane CoA (Certificate of Analysis) is a formal document that attests to Human Protaphane's compliance with Human Protaphane specifications and serves as a tool for batch-level quality control.

    Human Protaphane CoA mostly includes findings from lab analyses of a specific batch. For each Human Protaphane CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Human Protaphane may be tested according to a variety of international standards, such as European Pharmacopoeia (Human Protaphane EP), Human Protaphane JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Human Protaphane USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search